https://doi.org/10.1016/s0140-6736(18)32409-7
A
Aurelia Alexandru
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
57
Papers
9.4K
Citations
17
h-index
21
i10-index
Aurelia Alexandru is an academic researcher from Ovidius University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & Lung Cancer Diagnosis and Treatment. The author has an h-index of 17, co-authored 49 publications.
ORCID: 0009-0009-1420-1034Papers by this author
worksPembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
2019 · The Lancet · 3,270 citations
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
2019 · New England Journal of Medicine · 2,755 citations
https://doi.org/10.1056/nejmoa1910231
Perioperative Nivolumab in Resectable Lung Cancer
2024 · New England Journal of Medicine · 356 citations
https://doi.org/10.1056/nejmoa2311926
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
2021 · Journal of Thoracic Oncology · 318 citations
https://doi.org/10.1016/j.jtho.2021.09.010
Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’
2021 · ESMO Open · 6 citations
https://doi.org/10.1016/j.esmoop.2021.100345
Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib.
2007 · PubMed · 5 citations
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat